SH514

Overview

SH514 is an orally active IRF4 inhibitor ( IC 50 = 2.63 μM). SH514 binds to the IRF4-DBD domain, thereby inhibiting the interaction of IRF4 protein with DNA (KD = 1.28 μM). SH514 can inhibit the proliferation of IRF4-high-expressing NCI-H929 and MM.1R cells, and displays no cytotoxicity for normal cells. SH514 significantly downregulates the expression of IRF4 downstream target genes concentration-dependently. SH514 inhibits the expression of cell cycle-related proteins CDC2, Cyclin B1 , Cyclin D1 , Cyclin E1 , and CMYC in Multiple Myeloma cells. SH514 can induce DNA damage and increase the expression of γH2AX . SH514 effectively inhibits the proliferation of multiple myeloma tumors .

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > c-Myc | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-172085
• CAS No.: 3099543-90-2
• Molecular Formula: C32H38N2O4
• Molecular Weight: 514.66
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
• Availability: In-stock

Source

Original product source